Galderma and NovaBay Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo
24. September 2012 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
Global Study to Enroll Patients in Four Countries Worldwide
LAUSANNE, Switzerland and EMERYVILLE, Calif., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Galderma S.A., a global leading pharmaceutical company...
NovaBay Pharmaceuticals (NBY) Announces Expansion of Strategic Marketing Agreement for NeutroPhase(R) in Southeast Asia
14. September 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
NovaBay to Receive Up to $700,000 in Upfront and Milestone Payments
Agreement Includes Equity Investment by Naqu Area Pioneer Pharma Co., Ltd., of up to $5.5 million in Unregistered NovaBay Common...
NovaBay's NeutroPhase(R) Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
13. September 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
Case Study Presented at the 2012 Fall Symposium on Advanced Wound Care
EMERYVILLE, Calif., Sept. 13, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE-MKT:NBY), a clinical-stage...
NovaBay Pharmaceuticals Co-Authors Novel Study Demonstrating Chemical Impact of N-Chlorotaurine and NVC-422 on Bacterial Toxins
12. September 2012 14:15 ET
|
NovaBay Pharmaceuticals, Inc.
Study Presented at the 52nd ICAAC Validates Aganocide Compound's Mechanism of Action
EMERYVILLE, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE-MKT:NBY), a...
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 14th Annual Healthcare Conference
04. September 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Pharmaceuticals Receives Additional FDA 510(k) Clearance for NeutroPhase(R) Wound Cleanser
27. August 2012 09:15 ET
|
NovaBay Pharmaceuticals, Inc.
New Indications Gives Surgeons Greater Flexibility in the Management of Graft and Donor-SiteSurgical Procedures
NeutroPhase Now Available in Convenient Spray Pump
EMERYVILLE, Calif., Aug. 27,...
NovaBay Pharmaceuticals to Present at Southern California Investor Conference
20. August 2012 09:15 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 20, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective...
NovaBay Pharmaceuticals Provides Second Quarter 2012 Financial Results
09. August 2012 07:15 ET
|
NovaBay Pharmaceuticals, Inc.
Recent Highlights
Received FDA guidance at successful end-of-phase 2a meeting for NVC-422 program for treating impetigo; phase 2b study to initiate in the third quarter...
NovaBay Pharmaceuticals to Present at JMP Securities Healthcare Conference
05. Juli 2012 14:29 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 5, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), today announced that Dr. Ron Najafi, Chief Executive Officer, will present at the 7th Annual...
NovaBay Announces Successful End-of-Phase 2a FDA Meeting for Dermatology Program
06. Juni 2012 07:00 ET
|
NovaBay Pharmaceuticals, Inc.
Global Phase 2b Impetigo Clinical Study to Initiate in Third Quarter
EMERYVILLE, Calif., June 6, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY) today announced successful...